LIVN
$62.43
LivaNova PLC, a medical technology company, designs, develops, manufactures, markets, and sells products, therapies, and services in the United States, the United Kingdom, Germany, France, Italy, the Netherlands, Spain, Belgium, Poland, Sweden, Switzerland, Austria, Norway, Portugal, Finland, Denmark, and internationally.
Intraday
Recent News
Down 7.2% in 4 Weeks, Here's Why You Should You Buy the Dip in LivaNova (LIVN)
The heavy selling pressure might have exhausted for LivaNova (LIVN) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
All You Need to Know About LivaNova (LIVN) Rating Upgrade to Buy
LivaNova (LIVN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
A Look At LivaNova (LIVN) Valuation After Earnings Show Growth Guidance And A Swing To Net Loss
Why LivaNova’s latest earnings and guidance matter for investors LivaNova (LIVN) is drawing attention after its latest update combined new 2026 revenue guidance of 6% to 7% constant currency growth, a projected 1% currency tailwind, and a full year 2025 net loss. For investors, that mix of top line growth guidance and bottom line pressure raises practical questions about how the business is performing today and what the new outlook might imply for risk, valuation, and expectations. See our...
LivaNova Q4 Earnings Call Highlights
LivaNova (NASDAQ:LIVN) executives highlighted double-digit revenue growth, operating margin expansion and stronger cash generation in 2025, while outlining expectations for more moderate top-line growth in 2026 driven by continued momentum in cardiopulmonary and epilepsy and ongoing investment in in
LivaNova PLC (LIVN) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ...
LivaNova PLC (LIVN) reports robust revenue growth and strategic progress, despite supply constraints and market challenges.